Placenta Percreta Presents with Neoangiogenesis of Arteries with Von Willebrand Factor-Negative Endothelium

Alexander Schwickert1,4 · Wolfgang Henrich1 · Martin Vogel2 · Kerstin Melchior4 · Loreen Ehrlich4 · Matthias Ochs3 · Thorsten Braun1,4

Received: 13 November 2020 / Accepted: 2 October 2021 / Published online: 11 November 2021 © The Author(s) 2021

Abstract
In placenta percreta cases, large vessels are present on the precrete surface area. As these vessels are not found in normal placentation, we examined their histological structure for features that might explain the pathogenesis of neoangiogenesis induced by placenta accreta spectrum disorders (PAS). In two patients with placenta percreta (FIGO grade 3a) of the anterior uterine wall, one strikingly large vessel of 2 cm length was excised. The samples were formalin fixed and paraffin-embedded. Gomori trichrome staining was used to evaluate the muscular layers and Weigert-Van Gieson staining for elastic fibers. Immunohistochemical staining of the vessel endothelium was performed for Von Willebrand factor (VWF), platelet endothelial cell adhesion molecule (CD31), Ephrin B2, and EPH receptor B4. The structure of the vessel walls appeared artery-like. The vessel of patient one further exhibited an unordered muscular layer and a lack of elastic laminae, whereas these features appeared normal in the vessel of the other patient. The endothelium of both vessels stained VWF-negative and CD31-positive. In conclusion, this study showed VWF-negative vessel endothelia of epiploental arteries in placenta accreta spectrum. VWF is known to regulate artery formation, as the absence of VWF has been shown to cause enhanced vascularization. Therefore, we suppose that PAS provokes increased vascularization through suppression of VWF. This process might be associated with the immature vessel architecture as found in one of the vessels and Ephrin B2 and EPH receptor B4 negativity of both artery-like vessels. The underlying pathomechanism needs to be evaluated in a greater set of patients.

Keywords Placenta percreta · Placenta accreta spectrum · Abnormally invasive placenta · Neoangiogenesis · Immunohistochemistry · Von Willebrand factor

Introduction
The proper placental development is a key precondition for a healthy human pregnancy. The trophoblast invades the uterine decidua and subsequently the uterine spiral arteries, causing the arteries to dilate, to ensure continuously an adequate blood supply to the growing fetus [1]. In placenta accreta spectrum (PAS), this process is enhanced: Invasive extravillous trophoblast cells in PAS exhibit a more mesenchymal phenotype than in normal placentation, even until the third trimester [2, 3]. Placental tissue can be seen invading through the myometrium and serosa, sometimes even into the urinary bladder, parametria, or even the colon [4–6]. In addition to excessive extravillous trophoblastic invasion, abnormal maternal vascular remodeling (i.e., neoangiogenesis) is one of the driving factors of increased placental invasiveness [7–10]. Angiogenic growth factors, such as vascular endothelial growth factor and angiopoietin-2,
are upregulated in PAS lysates. Likewise, the expression of antiangiogenic proteins such as vascular endothelial growth factor receptor-2 (VEGFR-2), endothelial cell tyrosine kinase receptor (Tie-2), and soluble fms-like tyrosine kinase 1 (sflt-1) is reduced in syncytiotrophoblastic cells from PAS cases compared to normal placenta specimens [11]. In PAS, neoangiogenesis so far has been investigated on placental tissue samples. However, PAS is also characterized by large blood vessels that are present on the precrete surface area. Accordingly, subplacental hypervascularization is a well-known sign for placenta accreta spectrum in antenatal ultrasound scans [12, 13]. As these vessels are not found in normal placentation, they appear to be the result of PAS-induced vasculogenesis. The objective of this pilot study was to examine their histological structure for noteworthy features that might shed light on the pathogenesis of PAS-induced neoangiogenesis. Therefore, Gomori trichrome staining and Weigert-Van Gieson staining were used to assess the structure of the vessel walls and to determine whether they are veins or arteries. Additionally, to verify the histological classification of the vessels, immunohistochemical staining of the Eph family transmembrane ligand, Ephrin B2 (artery), and its receptor tyrosine kinase, EPH receptor B4 (vein), was performed [14, 15]. Finally, Von Willebrand factor (VWF) and platelet endothelial cell adhesion molecule (PECAM-1, CD31) were used to further characterize the endothelium of the vessels.

Methods

Sample Collection

Specimens were sampled from two patients at Charité University Hospital in Berlin with singleton pregnancies and placenta percreta of the anterior uterine wall FIGO grade of invasiveness 3a [16]. One strikingly large vessel (each of 2-cm length) was excised during caesarean section in both patients before the delivery of the fetus. Both women had no known internal diseases including Von Willebrand disease. They had provided signed informed consent for the examination of the samples under protocols approved by the Ethics Committees of Charité University Hospital in Berlin (No. EA1_031_15). The samples were formalin fixed immediately and paraffin-embedded for further analyses.

Patient Characteristics

Patient 1 is a 33-year-old G2P1 with one previous emergency cesarean section due to fetal distress at term 2 years earlier. In this pregnancy, a planned cesarean section was performed at 35 weeks after placenta percreta had been suspected in antenatal ultrasound scans. Intraoperatively, anterior placenta previa percreta (FIGO grade of invasiveness 3a, Fig. 1) was seen, and subtotal hysterectomy was performed in consent with the patient and completed family planning with a perioperative blood loss of 900 ml and without further complications [16].

Patient 2 is a 39-year-old G3P2. She had one previous cesarean section at 35 weeks due to placenta previa six years before this pregnancy. At that time, the placenta had presented intraoperatively as accrete (FIGO grade of invasiveness 1) and had been treated through sutures in the uterine cavity, B-Lynch-sutures, and the insertion of an intrauterine balloon [16]. In this pregnancy, the placenta previa percreta had been suspected in antenatal ultrasound scans. Therefore, a planned cesarean section was performed at 35 weeks. Intraoperatively, anterior placenta previa percreta (FIGO grade of invasiveness 3a) was seen, and subtotal hysterectomy was performed in consent with the patient and completed family planning.
planning with a perioperative blood loss of 2500 ml and without further complications [16].

**Gomori Trichrome Staining**

Paraffin Sects. 5-µm thick of the sagittal vessel were cut and dewaxed in xylene (2 × 5 min; J. T. Baker, Radnor, USA) and rehydrated in ethanol (2 min each in 96%, 70%, 50%; Carl Roth, Karlsruhe, Germany) followed by incubation for 30 min at 56 °C in Bouin solution. The sections were then rinsed under running water for 5 min. Incubation in Weigert iron hematoxylin (Merck, Darmstadt, Germany) for 10 min followed by rinsing under running water for another 10 min. This was followed by incubation in trichrome solution (Sigma-Aldrich, Taufkirchen, Germany) for 25 min. Differentiation was performed in 0.5% acetic acid (Merck, Darmstadt, Germany) for 2 min and 1 min followed by dehydration in ethanol (1 min 96%, 2 × 2 min 100%) and xylene (2 × 5 min). The sections were covered with Entellan® Neu (Merck, Darmstadt, Germany) and a cover glass. As a result of the staining, cytoplasm and erythrocytes are shown in red, fibrin and muscle pink, nuclei blue to black, and collagen fibers green.

**Weigert-Van Gieson Staining**

The procedure was carried out using the Elastica van Gieson staining kit (Merck, 1.15974.0002). About 5-µm-thick vessel paraffin sections were cut and deparaffinized in xylene (2 × 5 min; J. T. Baker, Radnor, USA) and rehydrated in ethanol (2 min each in 96%, 70%; Carl Roth, Karlsruhe, Germany) followed by incubation for 21 min in resorcinol-fuchsine solution. The sections were then rinsed under running water for 5 min and shortly rinsed with distilled water, followed by differentiation with 80% ethanol (immersed twice). Short rinse with distilled water. 3 min staining with Weigerts iron hematoxylin (Merck, Darmstadt, Germany), 10 min differentiation with running tap water, 3 min staining with van Gieson picrofuchsin solution. Short rinse in 70% ethanol, dehydration in ethanol (1 min 96%, 2 × 1 min 100%) and xylene (2 × 5 min). Covering with Entellan® Neu (Merck, Darmstadt, Germany) and a cover glass. As a result of the staining, elastic fibers are shown in black-violet, nuclei black blue/brown, collagen fibers red, and muscle cells/cytoplasm yellow.

**Immunohistochemical Staining of Endothelium Cells**

Immunohistochemical staining was performed on 5-µm paraffin-embedded sections. The sections were deparaffinized and rehydrated. Heat induced or protease induced pre-treatment of deparaffinized sections was carried out followed by washing with phosphate buffered saline (PBS, pH 7.3) 3 times. Endogenous peroxidases were blocked. Samples were washed 3 times with PBS. Blocking of unspecific binding sites was performed followed by incubation with the primary antibodies monoclonal mouse anti-human CD31 (M0823, Agilent, Santa Clara, USA, diluted at 1:20), polyclonal rabbit anti-human VWF (A0082; Agilent, Agilent, Santa Clara, USA, diluted at 1:100), polyclonal rabbit anti-human EFNB2 (HPA008999; Sigma Life Science, St. Louis, USA, diluted at 1:20), and polyclonal goat anti-human EphB4 (AF3038; R&D Systems, Inc., Minneapolis, USA, diluted at 1:30). After rinsing 3 times with PBS, the tissue was incubated with the secondary antibody. After rinsing 3 times with PBS, samples were incubated in avidin–biotin-complex (PK-4002, Elite Vectastain ABC Kit, Vector Laboratories). The sections were twice washed with PBS and Tris hydrochloride, followed by DAB staining (3,3′-diaminobenzidin tetrahydrochloride. D-5637, Sigma-Aldrich, Taufkirchen, Germany) and washing with Tris hydrochloride, PBS, and water. Counterstaining of the cell nuclei was performed with hematoxylin staining (Weigert’s iron hematoxylin kit for nuclear staining in histology, 1,159,730,002, Sigma-Aldrich) followed by dehydration. The slides were covered under exclusion of air with Entellan® Neu (107,961, Merck, Darmstadt, Germany) under a cover glass. Negative controls were incubated without the primary antibody (Supplementary Fig. 1). All details on specific reagents and antibodies can be found in Appendix 1.

**Image Acquisition and Processing**

Ten sections of every vessel were analyzed. Images of the tissue sections were acquired with the digital microscopy system Axioskop and the high-resolution digital color camera AxioCam MRc 5 (Zeiss, Oberkochen, Germany). Tissue sections were scanned at high magnification (×100, ×200) and processed with Axiovision 4.8.2 software (Zeiss, Oberkochen, Germany).

**Results**

Figure 1 shows the intraoperative photograph of the sampled blood vessel of patient one and Weigert-Van Gieson staining of the corresponding vessel. Images clearly demonstrate vessel localization on the surface of the percrete placenta.

**Structure of Vessel Walls**

Gomori trichrome staining showed that both vessels possess a clearly defined thick muscular layer and a vessel wall that appears not folded in the histological section, which characterized them most likely as arteries (Fig. 2). Vessel walls...
of both arteries showed a disorganized pattern of smooth muscle cells instead of a circular orientation as in other arteries [17]. Weigert-Van Gieson staining showed intact internal and external elastic laminae in the blood vessel of patient two (Fig. 2d), while elastic laminae were missing completely in the sample from patient one (Fig. 2b). Immunohistochemical staining of the endothelium for Ephrin B2 and EPH receptor B4 was negative in both vessels (Fig. 3).

VWF-Negative Endothelium

Immunohistochemical staining of VWF was negative in the endothelium of both patients’ arteries (Fig. 4a,c). However, both samples exhibited CD31-positive endothelial cells (Fig. 3b,d).

Discussion

Neoangiogenesis and abnormal maternal vascular remodeling are two driving forces of increased placental invasiveness [7, 8, 18]. This study describes two epiploental blood vessels sampled from percrete placentae. Gomori trichrome staining showed that both vessels possess a clearly defined thick muscular layer and a vessel wall that appears not folded in the histological section, which characterized them most likely as arteries (Fig. 2, Fig. 5). Both vessels exhibit a VWF-negative endothelium. This is remarkable, as VWF has recently been shown to regulate artery formation [19]. It appears plausible that PAS induces neoangiogenesis by downregulation of VWF expression. This dysregulation of new vessel formation might explain the immature architecture with a disorganized muscular layer in both and a lack of elastic layers in one of the examined artery-like vessels. Several studies have shown that the absence of VWF causes enhanced vascularization in both in vitro and in vivo [20, 21]. In Von Willebrand disease, this phenomenon can lead to angiogenesis and angiodysplasia [22]. However, VWF has
not yet been identified as a mediator of neoangiogenesis in PAS. Previous studies of PAS lysates have only described upregulation of angiogenic factors (vascular endothelial growth factor, angiopoietin, placental relaxin, relaxin family peptide receptor 1) and downregulation of antiangiogenic factors (vascular endothelial growth factor receptor 2, endothelial cell tyrosine kinase receptor 2, soluble fms-like tyrosine kinase 1) [7, 23]. Suppression of VWF might prove a further pathway that stimulates neoangiogenesis in PAS. It remains unclear, by which mechanism PAS modulates VWF expression. Placental hypoxia—due to an implantation of the placenta on a uterine scar—has been discussed as one factor that stimulates increased placental invasiveness [24–26]. It might also play a role in PAS-induced neoangiogenesis. Interestingly, though the blood vessels histologically showed an artery-like phenotype, the endothelium of both vessels stained negative for Ephrin B2, a unique molecular marker for arterial endothelial cells. A similar phenomenon has been shown in mouse embryos compound mutant for Foxc1 and Foxc2, two closely related Fox transcription factors [27]. The animals exhibit arteriovenous malformations and also lack induction of arterial markers such as Ephrin B2. The authors suggest that mutant endothelial cells “fail to acquire an arterial fate” [27]. We suspect that a similar mechanism—maybe associated with the lack of VWF—might be involved in neoangiogenesis in cases of PAS. The lack of elastic laminae found in one of the examined blood vessels can be explained by the fact that in PAS, extravillous trophoblast cells degrade elastic fibers within vessel walls through the expression of elastolytic proteases MMP-2, MMP-7, and MMP-9 [18, 28, 29]. A limitation of this pilot study stems from the fact that only specimens from two patients were examined.
Conclusion

VWF is absent in the endothelial cells of the examined epiplacental blood vessels. The absence of VWF has been shown to induce neoangiogenesis and angiodysplasia. The endothelia of the examined artery-like vessels do not express...
Ephrin B2 and EPH receptor B4 – both unique molecular markers for arterial and venous endothelial cells, respectively. The next step is to evaluate the pathomechanism of this newly found phenomenon in PAS. This might eventually help in developing suitable treatment or even prevention strategies.

Appendix 1

Supplementary Information The online version contains supplementary material available at https://doi.org/10.1007/s43032-021-00763-4.

Acknowledgements We thank Dr. R.C. Rancourt for language editing and proofreading. We are also indebted to all the staff of our Department of Obstetrics.

Author Contribution All authors contributed substantially in conception and planning of the study. TB performed the caesarean sections and the excision of the vessels. KM and LE performed the histological and immunohistochemical staining. AS analyzed the staining, collected the data, and drafted the first manuscript. All authors contributed to the data analysis and interpretation of the data. AS and TB revised the manuscript together. All authors reviewed and approved the final submitted version of the manuscript.

Funding Open Access funding enabled and organized by Projekt DEAL. This study is supported by the university research fund of Charité – Universitätsmedizin Berlin, Germany (51517172–01).

Data Availability No statistical analyses were performed. All material is available upon request.

Code Availability Not applicable.

Declarations

Ethics Approval The study was approved by the Regional Ethics Committee in Berlin, Germany, No. EA1_031_15 on 31 July 2015.

Consent to Participate All women had provided signed informed consent for the examination of the samples as well as collection of anonymized clinical information as approved by the Regional Ethics Committee in Berlin, Germany.

Consent for Publication All authors consent to the publication of this paper.

Conflict of Interest The authors declare no competing interests.

References

1. Lyall F. The human placental bed revisited. Placenta. 2002;23(8–9):555–62.
2. Illsley NP, DaSilva-Arnold SC, Zamudio S, Alvarez M, Al-Khan A. Trophoblast invasion: Lessons from abnormally invasive placenta (placenta accreta). Placenta. 2020;102:61–6.
3. Duzyj CM, Buhimschi IA, Matowa H, et al. The invasive phenotype of placenta accreta extravillous trophoblasts associates with loss of E-cadherin. Placenta. 2015;36(6):645–51.
4. Vigil H, Herschorn S, Kodama R, Barrett J. Placenta percreta into the urinary bladder: the importance of the urologist. Can J Urol. 2019;26(2):9736–9.
5. Chen HQ, Zou SH, Yang JB, Zhang Y, Cai J, Wang ZI. Placenta percreta with colon involvement in a twin pregnancy: case report and literature review. Clin Exp Obstet Gynecol. 2017;44(3):461–3.
6. Murji A, Kingdom J. Placenta Percreta Involving Maternal Bladder. N Engl J Med. 2019;381(7):e12.
7. Bartels HC, Postle JD, Downey P, Brennan DJ. Placenta accreta spectrum: a review of pathology, molecular biology, and biomarkers. Dis Markers. 2018;2018:1507674.
8. Tanbirou P, Crum CP, Parast MM. Pathophysiology of placenta creta: the role of decidua and extravillous trophoblast. Placenta. 2008;29(7):639–45.
9. Jauniaux E, Jurkovic D. Placenta accreta: pathogenesis of a 20th century iatrogenic uterine disease. Placenta. 2012;33(4):244–51.
10. Schwickt A, Chantaine F, Ehrlich L, et al. Maternal Serum VEGF Predicts Abnormally Invasive Placenta Better than NT-proBNP: a Multicenter Case-Control Study. Reprod Sci. 2021;28(2):361–70.
11. Tseng J-J, Chou M-M. Differential expression of growth-, angiogenesis- and invasion-related factors in the development of placenta accreta. Taiwan J Obstet Gynecol. 2006;45(2):100–6.
12. Collins SL, Ashcroft A, Braun T, et al. Proposal for standardized ultrasound descriptors of abnormally invasive placenta (AIP). Ultrasound Obstet Gynecol. 2016;47(3):271–5.
13. Jauniaux E, Collins S, Burton GI. Placenta accreta spectrum: Pathophysiology and evidence-based anatomy for prenatal ultrasound imaging. Am J Obstet Gynecol. 2018;218(1):75–87.
14. Wang HU, Chen Z-F, Anderson DJ. Molecular distinction and angiogenic interaction between embryonic arteries and veins revealed by ephrin-B2 and its receptor Eph-B4. Cell. 1998;93(5):741–53.
15. dela Paz NG, D’Amore PA. Arterial versus venous endothelial cells. Cell Tissue Res. 2009;335(1):5–16.
16. Jauniaux E, Ayres-de-Campos D, Langhoff-Roos J, Fox KA, Collins S. FIGO classification for the clinical diagnosis of placenta accreta spectrum disorders. Int J Gynaecol Obstet. 2019;146(1):20–4.
17. Pugsley MK, Tabrizchi R. The vascular system. J Pharmacol Toxicol Methods. 2000;44(2):333–40.
18. Harris LK. Review: Trophoblast-vascular cell interactions in early pregnancy: how to remodel a vessel. Placenta. 2010;31(Suppl):S93–8.
19. Randi AM, Laffan MA. Von Willebrand factor and angiogenesis: basic and applied issues. J Thromb Haemost. 2017;15(1):13–20.
20. Starke RD, Ferraro F, Paschalaki KE, et al. Endothelial von Willebrand factor regulates angiogenesis. Blood. 2011;117(3):1071–80.
### Table 1 Immunohistochemical staining protocols

| Target antigen | Heat-induced pretreatment | Blocking of endogenous peroxidases | Blocking of unspecific binding sites | Primary antibody | Secondary antibody | Incubation in avidin–biotin-complex | DAB staining |
|----------------|---------------------------|-----------------------------------|-------------------------------------|------------------|-------------------|------------------------------------|-------------|
| CD31           | Dako Target Retrieval Solution (S1700, Dako, Agilent, Santa Clara, United States) for 20 min at 95 °C | 3% Hydrogen peroxide for 20 min at room temperature | 2% Normal horse serum (NHS, PK-4002, Elite Vectastain ABC Kit, Vector Laboratories, Germany) for 30 min | Monoclonal mouse anti-human CD31, number: M0823, Agilent, Santa Clara, USA, diluted at 1:20 in 2% NHS for 75 min | Biotinylated horse anti-mouse IgG, PK-4002, Vector Laboratories, Germany, diluted at 1:200 in 2% NHS for 30 min | 30 min | 30 min |
| Von Willebrand factor | Protease from Streptomyces griseus (P5147-5G, Sigma-Aldrich, Taufkirchen, Germany) for 5 min at 37 °C | 3% Hydrogen peroxide and methanol for 20 min | 2% Normal goat serum (NGS, S-1000, Vector Laboratories, Germany) for 60 min | Polyclonal rabbit anti-human VWF, number: A0082; Agilent, Agilent, Santa Clara, USA, diluted at 1:100 in antibody dilution and incubated overnight at 4 °C | Biotinylated goat anti-rabbit, BA-1000, Vector Laboratories, Linaris GmbH, Wertheim-Bettingen, Germany, diluted at 1:500 in antibody dilution for 2 h | 30 min | 30 min |
| Ephrin B2      | Target Retrieval Solution (10x) (S1699, DakoCytomation/Agilent Technologies Singapore Pte Ltd., Singapore) in a steamer for 10 min followed by 20 min at room temperature | 3% Hydrogen peroxide and for 15 min | 2% Normal goat serum (BA-1000/Vector Laboratories Inc., Burlingame, USA) for 90 min | Polyclonal rabbit anti-human EFN1B2, HPA008999, Sigma Life Science, St. Louis, USA, diluted at 1:20 in PBS and incubated overnight at 4 °C | Biotinylated goat anti-rabbit, BA-1000, Vector Laboratories, Linaris GmbH, Wertheim-Bettingen, Germany, diluted at 1:200 in PBS for 2 h | 120 min | 15 min |
| EPH receptor B4 | Target Retrieval Solution (10x) (S1699, DakoCytomation/Agilent Technologies Singapore Pte Ltd., Singapore) in a water bath at 95 °C for 20 min followed by 20 min at room temperature | 3% Hydrogen peroxide and for 15 min | 5% Milk powder in PBS for 30 min | Polyclonal goat anti-human EphB4, number: AF3038; R&D Systems, Inc., Minneapolis, USA, diluted at 1:30 in PBS and incubated overnight at 4 °C | Polyclonal donkey anti-goat VisUcyte HRP Polymer Antibody (VC004, R&D Systems, Inc., Minneapolis, USA) diluted at 1:300 in PBS for 2 h | 60 min | 15 min |

All non-specified incubations were performed at room temperature.
21. Xu H, Cao Y, Yang X, et al. ADAMTS13 controls vascular remodeling by modifying VWF reactivity during stroke recovery. Blood. 2017;130(1):11–22.
22. Randi AM. Endothelial dysfunction in von Willebrand disease: angiogenesis and angiodysplasia. Thromb Res. 2016;141(Suppl 2):S55–8.
23. Goh W, Yamamoto SY, Thompson KS, Bryant-Greenwood GD. Relaxin, its receptor (RXFP1), and insulin-like peptide 4 expression through gestation and in placenta accreta. Reprod Sci. 2013;20(8):968–80.
24. Öztas E, Özler S, Ergin M, et al. Decreased oxidative stress may contribute to the disease process in placenta accreta. Turk J Med Sci. 2017;47(4):1180–4.
25. Schoots MH, Gordijn SJ, Scherjon SA, van Goor H, Hillebrands J-L. Oxidative stress in placental pathology. Placenta. 2018;69:153–61.
26. Roeder HA, Cramer SF, Leppert PC. A look at uterine wound healing through a histopathological study of uterine scars. Reprod Sci. 2012;19(5):463–73.
27. Seo S, Fujita H, Nakano A, Kang M, Duarte A, Kume T. The forkhead transcription factors, Foxc1 and Foxc2, are required for arterial specification and lymphatic sprouting during vascular development. Dev Biol. 2006;294(2):458–70.
28. László A, Sohár I, Falkay G, Kovács A, Halmos V, Szabó J. Physiological values of cysteine and metalloproteinase activities in chorionic villi. Acta Obstet Gynecol Scand. 1990;69(5):397–8.
29. Staun-Ram E, Goldman S, Gabarin D, Shalev E. Expression and importance of matrix metalloproteinase 2 and 9 (MMP-2 and -9) in human trophoblast invasion. Reprod Biol Endocrinol. 2004;2:59.

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.